Aberdeen Group plc Buys 14,792 Shares of The Clorox Company $CLX

Aberdeen Group plc increased its stake in shares of The Clorox Company (NYSE:CLX) by 12.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 137,194 shares of the company’s stock after purchasing an additional 14,792 shares during the quarter. Aberdeen Group plc owned about 0.11% of Clorox worth $16,473,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Clorox by 0.4% during the first quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company’s stock valued at $2,293,135,000 after purchasing an additional 65,924 shares during the last quarter. Northern Trust Corp boosted its stake in Clorox by 2.3% in the first quarter. Northern Trust Corp now owns 1,528,920 shares of the company’s stock valued at $225,133,000 after acquiring an additional 34,655 shares during the last quarter. Invesco Ltd. boosted its stake in Clorox by 7.4% in the first quarter. Invesco Ltd. now owns 1,361,710 shares of the company’s stock valued at $200,512,000 after acquiring an additional 94,371 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Clorox by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company’s stock valued at $170,406,000 after acquiring an additional 41,485 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its stake in Clorox by 118.8% in the first quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock valued at $159,699,000 after acquiring an additional 589,544 shares during the last quarter. 78.53% of the stock is owned by institutional investors.

Insider Activity at Clorox

In related news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares in the company, valued at $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.63% of the stock is currently owned by insiders.

Clorox Trading Down 0.7%

CLX opened at $119.50 on Wednesday. The Clorox Company has a twelve month low of $116.53 and a twelve month high of $171.37. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The firm’s fifty day moving average is $122.02 and its two-hundred day moving average is $128.33. The firm has a market cap of $14.55 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 1.00 and a beta of 0.52.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the business posted $1.82 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Clorox Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Wednesday, October 22nd. Clorox’s dividend payout ratio (DPR) is presently 76.07%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Clorox from $135.00 to $127.00 and set a “neutral” rating on the stock in a research note on Friday, October 10th. Wells Fargo & Company reduced their price objective on shares of Clorox from $130.00 to $125.00 and set an “equal weight” rating on the stock in a research note on Thursday, September 25th. Jefferies Financial Group reduced their price objective on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. The Goldman Sachs Group cut their target price on shares of Clorox from $115.00 to $110.00 and set a “sell” rating on the stock in a report on Wednesday, October 1st. Finally, UBS Group cut their target price on shares of Clorox from $134.00 to $128.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $131.64.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.